Sarepta gets path forward for muscular dystrophy drug
April 21, 2014 at 06:55 AM EDT
Sarepta Therapeutics got the go-ahead to file for approval of its experimental drug for Duchenne muscular dystrophy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.